Precursors of pancreatic cancer: PanIN, IPMN, MCN
- Process
Pancreatic cancer develops over years from small changes in duct cells, gaining one genetic hit after another.
What it is
Invasive pancreatic ductal adenocarcinoma arises from non-invasive precursors. The most common is pancreatic intraepithelial neoplasia (PanIN), a microscopic lesion of small ducts. Larger, cystic precursors are IPMN and mucinous cystic neoplasm. The progression follows a stepwise molecular model: telomere shortening and KRAS activation early, CDKN2A (p16) loss in intermediate lesions, and TP53 and SMAD4 loss late at the transition to invasive cancer.
Step by step
- Telomere shortening in duct cells favours chromosomal instability.
- KRAS activation drives proliferation: low-grade PanIN.
- CDKN2A loss removes the p16 brake on the cell cycle.
- TP53 loss allows DNA damage to accumulate: high-grade PanIN.
- SMAD4 loss frees cells from TGF-β growth control and favours invasion.
- Invasive ductal adenocarcinoma with desmoplasia develops.
Precursors of pancreatic ductal adenocarcinoma
| Precursor | Size and site | Key features | Molecular |
|---|---|---|---|
| PanIN | Microscopic, small ducts | Columnar mucinous epithelium, flat or papillary; low or high grade | KRAS early, then CDKN2A, TP53, SMAD4 |
| IPMN | Visible cyst in main or branch ducts | Papillary mucinous epithelium, duct communication | GNAS, KRAS, RNF43 |
| Mucinous cystic neoplasm | Cyst in body or tail, no duct connection | Mucinous epithelium over ovarian stroma | KRAS, RNF43 |
Markers
- Loss of SMAD4 (DPC4) immunostain
- p53 overexpression or loss
- MUC1 and MUC2 (IPMN subtypes)
Test yourself
Think of the answer, then tap the question to see it.
What is the most common precursor of pancreatic ductal adenocarcinoma?
Pancreatic intraepithelial neoplasia (PanIN), a microscopic lesion of small ducts.
Which mutation is the earliest in the PanIN to carcinoma sequence?
An activating KRAS mutation.
Which tumour suppressor genes are typically lost late, at the transition to invasive cancer?
TP53 and SMAD4 (DPC4).
Connections
Educational content on the mechanisms of disease; not a diagnostic or treatment guide and no substitute for a health professional's advice. No doses are given.
Sources: Pancreatic Cancer (StatPearls (NCBI Bookshelf), 2024); Pancreatic Cancer Treatment (PDQ®) - NCI (National Cancer Institute, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.